The goal of the Tissue Culture Facility is to provide all UNC Lineberger Comprehensive Cancer Center Members with expert services and quality controlled and innovative materials required for basic and clinical research involving in vitro cell culture and molecular biology needs. TCF services include four main """"""""divisions"""""""": Cell Culture (services and products), Clinical Support (through its Immortalization of Human Bcells using EBV and banking of patient samples in its Genetic Repository), Molecular Biology Materials Support (over 700 items available conveniently on site and 75,000 via free overnight shipping), and its large scale centralized cell production. The TCF is led by Stephen Oglesbee, Director, with over 27 years of directly related experience. The Core adds value to the Center by providing a range of specialized services, centralized functions, and cost savings and convenience. Highlights of research supported by the TCF include:a high human B-cell transformation rates (over 99%) and the development and testing of a new soon to be patented and/or licensed, significantly discounted isolation and growth medium for epithelial cells. Future plans for the TCF include expansion of its human B-cell immortalization program in support of numerous projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-34
Application #
7751852
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-12-01
Budget End
2009-11-30
Support Year
34
Fiscal Year
2009
Total Cost
$277,201
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Smith, Jennifer S; Des Marais, Andrea C; Deal, Allison M et al. (2018) Mailed Human Papillomavirus Self-Collection With Papanicolaou Test Referral for Infrequently Screened Women in the United States. Sex Transm Dis 45:42-48
Morris, Michael J; Rumble, R Bryan; Basch, Ethan et al. (2018) Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36:1521-1539
Hisada, Yohei; Thålin, Charlotte; Lundström, Staffan et al. (2018) Comparison of microvesicle tissue factor activity in non-cancer severely ill patients and cancer patients. Thromb Res 165:1-5
Westmoreland, Katherine D; El-Mallawany, Nader K; Kazembe, Peter et al. (2018) Dissecting heterogeneous outcomes for paediatric Burkitt lymphoma in Malawi after anthracycline-based treatment. Br J Haematol 181:853-854
Kulis, Michael; Yue, Xiaohong; Guo, Rishu et al. (2018) High- and low-dose oral immunotherapy similarly suppress pro-allergic cytokines and basophil activation in young children. Clin Exp Allergy :
Malta, Tathiane M; Sokolov, Artem; Gentles, Andrew J et al. (2018) Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell 173:338-354.e15
Lund, Jennifer L; Sanoff, Hanna K; Peacock Hinton, Sharon et al. (2018) Potential Medication-Related Problems in Older Breast, Colon, and Lung Cancer Patients in the United States. Cancer Epidemiol Biomarkers Prev 27:41-49
Wu, Shih-Ying; Fix, Samantha M; Arena, Christopher B et al. (2018) Focused ultrasound-facilitated brain drug delivery using optimized nanodroplets: vaporization efficiency dictates large molecular delivery. Phys Med Biol 63:035002
Juliano, Rudolph L; Wang, Ling; Tavares, Francis et al. (2018) Structure-activity relationships and cellular mechanism of action of small molecules that enhance the delivery of oligonucleotides. Nucleic Acids Res 46:1601-1613
El-Mallawany, Nader Kim; Kamiyango, William; Villiera, Jimmy et al. (2018) Proposal of a Risk-Stratification Platform to Address Distinct Clinical Features of Pediatric Kaposi Sarcoma in Lilongwe, Malawi. J Glob Oncol :1-7

Showing the most recent 10 out of 1525 publications